Catawba Research Announces Strategic Partnership With PharmaLegacy Laboratories

Collaboration to Enhance Preclinical and Clinical Research Capabilities

CHARLOTTE, N.C.; Oct. 22, 2024 (Business Wire)Catawba Research, a leading global full-service Clinical Research Organization (CRO), is proud to announce a strategic partnership with PharmaLegacy Laboratories, a recognized leader in preclinical contract research services. This collaboration is set to leverage both companies’ strengths, driving innovation and excellence in drug development and provides Catawba Research with new access to China, further expanding their APAC capabilities.

PharmaLegacy Laboratories specializes in advanced preclinical models and pharmacology research, with an emphasis on supporting biotechnology and pharmaceutical companies in their drug discovery and development efforts. The collaboration enhances Catawba Research’s outstanding agile solution offerings and scientific focus. 

“We are thrilled to partner with PharmaLegacy,” said Andy Silverman, CEO of Catawba Research. “Their depth of expertise in preclinical research aligns perfectly with Catawba’s commitment to delivering high-quality, efficient clinical trial management. This collaboration allows us to offer end-to-end solutions for our clients, accelerating the drug development process while maintaining the highest standards of scientific integrity.”

Jeff Duan, CEO of PharmaLegacy, added, “Catawba Research has a stellar reputation in the clinical research space, and we believe that by combining our capabilities, we can offer our clients a truly comprehensive research experience. Together, we can help to bring new therapies to market to benefit patients more effectively and efficiently.”

The partnership will streamline drug development for our customers by offering a single source for both preclinical and clinical trial services. The combined expertise will ensure that drug candidates are tested and validated using the most rigorous methods, enabling faster and more reliable delivery of new treatments to patients in need.

About Catawba Research

Catawba Research is a global full-service Clinical Research Organization that provides oversight, management, and implementation for Phase II and Phase III clinical trials. Headquartered in Charlotte, NC, Catawba works with drug-development sponsors to bring innovative treatments to the global market.

About PharmaLegacy Laboratories

PharmaLegacy Laboratories, headquartered in Shanghai, a global leading preclinical Contract Research Organization, is dedicated to accelerating the adoption of new therapies, resulting from the integration of new drug R&D and translational research, by providing the most clinically relevant, science-based specialty pharmacology and toxicology services to global pharmaceutical and biotech companies enabling the development of new drugs and therapies.

PharmaLegacy acquires preclinical CRO BTS Research, strengthening its preclinical services and expanding laboratory operations into North America

PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO).

As a reputable CRO providing preclinical pharmacology services to clients worldwide, PharmaLegacy’s acquisition of BTS Research is an important step in its continuing growth. San Diego is a significant global R&D hub and the acquisition allows Pharmalegacy to join the greater community while also strengthening and expanding PharmaLegacy’s global research capabilities and service offerings.

“PharmaLegacy has been serving the US markets for many years, and a local presence in San Diego biotechnology scene will accelerate our growth,” said Jeff Duan, founder & CEO of PharmaLegacy. “This acquisition will allow us to better serve clients across the US and North America while increasing our study capacity and providing more flexibility for all of our clients. As such, it is a crucial step to becoming an industry-leading preclinical CRO.”

The synergy between PharmaLegacy and BTS Research creates a powerful combination that will further allow pharmaceutical, biotechnology, medical device, and diagnostics companies to obtain rapid and reliable pharmacology data to advance cures for patients. The combined companies possess decades of experience providing preclinical research services, and the acquisition of BTS will allow PharmaLegacy to add GLP toxicology services to our complete offering of pharmacology services.

“We are truly excited to be joining the PharmaLegacy family,” said Sami Abunadi, President of BTS Research. “As we further integrate our capabilities and knowledge, we will be able to deliver best-in-class research services to support drug, device, and diagnostic pipelines. This joining of forces will create a highly competitive global CRO.”

 

About PharmaLegacy Laboratories:

PharmaLegacy is a CRO founded in 2008 which provides efficient and cost-effective preclinical in vitro and in vivo pharmacology studies to life science organizations. PharmaLegacy boasts a thousand of validated in vitro and in vivo services across over 40 different diseases, and has contributed to over 400 IND applications.

For more information on PharmaLegacy, visit https://www.pharmalegacy.com/

 

About BTS Research:

BTS Research is a San Diego-based Contract Research Organization that delivers GLP and Non-GLP biological services to clients in pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and related industries, and has roots dating back to 2001 (formerly Bio-Quant, Inc. and BioTox Sciences). The Company was founded in 2007 and acquired Bio-Quant in 2011.

For more information on BTS Research, visit https://btsresearch.com/

 

Media contact:

Michael Zhang

Sr. Vice President of PharmaLegacy

michael.zhang@pharmalegacy.com

PHARMALEGACY TO EXHIBIT AT BIO-EUROPE 2024 NOVEMBER 4-6 2024 IN STOCKHOLM SWEDEN

PharmaLegacy will be exhibiting at the Bio-Europe November 4-6 in Stockholm. You can book a meeting with us here  to discuss the how to bolster the global biotechnology industry, together.

You can register here for Bio-Europe

We hope to see you in Stockholm!

 

 

PHARMALEGACY TO EXHIBIT AT BIOTECH SUMMIT 2024 OCTOBER 10-11 2024 IN INNSBRUCK, AUSTRIA

PharmaLegacy will be exhibiting at the Biotech Summit October 10-11 in Innsbruck. You can book a meeting with us here  to discuss the latest trends and developments in biotechnology.

You can register here for Biotech Summit 2024

We hope to see you in Innsbruck!

 

 

PHARMALEGACY TO EXHIBIT AT NLS DAYS 2024 SEPTEMBER 18-19 2024 IN MALMÖ, SWEDEN

PharmaLegacy will be exhibiting at the NLS Days – the largest Nordic partnering conference dedicated to the life science industry- September 18-19 in Malmö. Book a meeting with us  and let’s discuss the future of life sciences together.

You can register here for NLS Days 2024

We hope to see you in Malmö!

PHARMALEGACY TO EXHIBIT AT ARVO MAY 5-9 2024 IN SEATTLE, WASHINGTON

PharmaLegacy will be exhibiting at the 2024 meeting of the Association for Research in Vision & Ophthalmology May 5–9 in Seattle. Visit us at booth #4703 and discuss predicting outcomes for potential treatments with our latest ophthalmology models.

You can register here for ARVO 2024

We hope to see you in Seattle!